Amy Parison Biography and Net Worth

CFO of Editas Medicine

Amy Parison is Chief Financial Officer of Editas Medicine. She joined Editas Medicine in August 2022 and has served in multiple roles of increasing responsibility including Senior Vice President of Finance, Vice President of Finance, and Corporate Controller. Her strategic vision and leadership have been instrumental in steering key enterprise initiatives and fostering a culture of financial excellence.

Prior to her roles at Editas, Amy was the Corporate Controller at Rubius Therapeutics, Inc., a biotech that aimed to develop cellular medicines. At Rubius, she built and led the finance team following the Company’s IPO, and played a critical role in securing the Company’s equity and debt financings, and development of enterprise-wide business processes including financial processes and procedures. Over her seven-year career at Vertex Pharmaceuticals, Amy held various roles of increasing responsibility within the accounting and finance team, including supporting the Company’s business development efforts and international expansion of the finance and accounting teams. Amy began her career at PricewaterhouseCoopers, LLP, where she worked in audit.

Amy holds a Bachelor of Science and a Master of Accounting, both from Babson College.

What is Amy Parison's net worth?: The estimated net worth of Amy Parison is at least $45.38 thousand as of March 3rd, 2026. Ms. Parison owns 15,434 shares of Editas Medicine stock worth more than $45,376 as of April 11th. This net worth estimate does not reflect any other assets that Ms. Parison may own. Learn More about Amy Parison's net worth.
How do I contact Amy Parison?: The corporate mailing address for Ms. Parison and other Editas Medicine executives is 11 Hurley Street, Cambridge MA, 02141. Editas Medicine can also be reached via phone at (617) 401-9000 and via email at [email protected]. Learn More on Amy Parison's contact information.
Has Amy Parison been buying or selling shares of Editas Medicine?: Amy Parison has not been actively trading shares of Editas Medicine over the course of the past ninety days. Most recently, Amy Parison sold 474 shares of the business's stock in a transaction on Tuesday, March 3rd. The shares were sold at an average price of $2.02, for a transaction totalling $957.48. Following the completion of the sale, the chief financial officer now directly owns 15,434 shares of the company's stock, valued at $31,176.68. Learn More on Amy Parison's trading history.
Who are Editas Medicine's active insiders?: Editas Medicine's insider roster includes Katrine Bosley (CEO), Linda Burkly (Executive Vice President and Chief Scientific Officer), Bruce Eaton (EVP), Lisa Michaels (EVP), James Mullen (CEO), Gilmore O'neill (President & CEO), Amy Parison (CFO), and Michelle Robertson (CFO). Learn More on Editas Medicine's active insiders.
Are insiders buying or selling shares of Editas Medicine?: During the last year, insiders at the sold shares 11 times. They sold a total of 35,558 shares worth more than $70,586.08. The most recent insider tranaction occured on March, 3rd when CEO Gilmore Neil O'neill sold 5,394 shares worth more than $10,895.88. Insiders at Editas Medicine own 2.1% of the company. Learn More about insider trades at Editas Medicine.
Information on this page was last updated on 3/3/2026.

Amy Parison Insider Trading History at Editas Medicine

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/3/2026	Sell	474	$2.02	$957.48	15,434
12/3/2025	Sell	461	$2.15	$991.15	15,908
8/7/2025	Sell	679	$2.58	$1,751.82	16,827
6/3/2025	Sell	446	$1.72	$767.12	17,506

Amy Parison Buying and Selling Activity at Editas Medicine

Editas Medicine Company Overview

Editas Medicine, Inc., a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary gene editing platform based on CRISPR technology. The company develops EDIT-101, which is in Phase 1/2 BRILLIANCE trial for Leber Congenital Amaurosis; and reni-cel, a clinical development gene-edited medicine to treat sickle cell disease and transfusion-dependent beta-thalassemia. In addition, the company is developing alpha-beta T cells for solid and liquid tumors; and gamma delta T cell therapies to treat cancer. It has a research collaboration with Juno Therapeutics, Inc. to develop engineered T cells for cancer; strategic alliance and option agreement with Allergan Pharmaceuticals International Limited. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine, Inc. in November 2013. Editas Medicine, Inc. was incorporated in 2013 and is based in Cambridge, Massachusetts.

Today's Range

Now: $2.94

$2.79

$2.95

50 Day Range

MA: $2.22

$1.67

$2.94

2 Week Range

Now: $2.94

$1.08

$4.54

Volume

1,590,083 shs

Average Volume

1,350,583 shs

Market Capitalization

$287.74 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

2.04